Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated ...

Apixaban, an anticoagulant drug is used in treating venous thromboembolic events. A summary of it’s metabolism, pharmacologic properties and it’s drug interactions have been presented in this ...

Update, March 1, 5 PM: Ramsay Baghadi of the RPM Report says that the Cardiorenal committee will take up the apixaban NDA on Mary 22 and the rivaroxaban supplemental NDA for the ACS indication on ...

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism ...

Apixaban was not superior to standard of care antithrombotic treatment for preventing thrombotic or bleeding events after successful transcatheter aortic valve replacement, regardless of ...

Unlike rivaroxaban, apixaban can be administered with or without food so that patients do not have to plan medication around a meal. In patients with CKD, label indications advise not prescribing the ...

A 2012 study using indirect comparisons indicated that apixaban had a lower risk of major hemorrhage compared with other DOACs. And a 2018 analysis based on claims data showed that apixaban carried ...

Although apixaban caused much lower rates of major bleeding in frail patients when compared to Coumadin (eg, 40.7 such events per 1,000 person-years for dabigatran and 83.4 such events per 1,000 ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a ...

Apixaban was also associated with a 49% lower risk of gastrointestinal or intracranial bleeding vs rivaroxaban (HR, 0.51; 95% CI, 0.41-0.62).